Thymoma

Gripp, Stephan; Hilgers, Kerstin; Würm, Reinhard; Schmitt, G

doi:10.1002/(sici)1097-0142(19981015)83:8<1495::aid-cncr4>3.0.co;2-o

Cited by 92 publications

(16 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several investigations have demonstrated a bias for male or female sex as well as no predilection; in this study, no significant difference in incidence was noted between genders. 6 , 7 , 8 , 9 , 10 , 11 Relative frequencies of thymoma subtype in this study were A (7.5%), AB (22.5%), B1 (25.0%), B2 (20.0%), and B3 (15.0%), similar to those observed in the literature with subtype A (11%), AB (23%), B1 (17%), and B2 (28%), and B3 (21%). 7 …”

Section: Discussionsupporting

confidence: 89%

“…Several investigations have demonstrated a bias for male or female sex as well as no predilection; in this study, no significant difference in incidence was noted between genders. [6][7][8][9][10][11] Relative frequencies of thymoma subtype in this study were A (7.5%), AB (22.5%), B1 (25.0%), B2 (20.0%), and B3 (15.0%), similar to those observed in the literature with subtype A (11%), AB (23%), B1 (17%), and B2 (28%), and B3 (21%). 7 The most significant observed difference between thymoma subtypes on presentation is age at diagnosis.…”

Section: Discussionsupporting

confidence: 88%

“…In our cohort, patients with thymic carcinoma presented with more advanced disease, which is consistent with the literature. 10 Four patients had stage IV disease, of which three died within 18 months due to disease progression. Four of seven patients received surgery; these patients had an overall better survival.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical characteristics, prognostic factors, and long‐term outcomes associated with epithelial malignancies of the thymus: A 20‐year single‐institution experience

Altshuler

Mathavan

et al. 2022

Cancer Reports

View full text Add to dashboard Cite

Background: Thymic epithelial tumors are rare and include thymomas and thymic carcinomas. There is scarce literature characterizing prognostic factors and long-term outcomes in these tumors.Aims: This review aims to describe disease features of thymomas and thymic carcinomas and to report clinical differences among thymoma histological subtypes.Methods and Results: A retrospective chart review was performed at the University of Florida Shands Hospital, a tertiary care academic medical center in Gainesville, Florida, USA. The review included clinical data of adults with thymic epithelial tumors diagnosed between 2001 and 2021. Significant associations among demographics, histology, stage, and outcomes were investigated. Thymoma subgroup analysis was performed using histological subtype and sex. Forty patients with thymoma and seven patients with thymic carcinoma were included in the final analysis. Among those with thymomas, patients with subtype B1, B2, or B3 tumors were younger, had larger tumors, and presented with higher stage disease when compared to those with subtypes A or AB. Tumor recurrence was most common in subtype B2 and B3 tumors (50.0% and 16.7% vs. 0%; p < .01). However, there was no significant difference in overall survival between histologic subtypes. Compared to females, males with thymomas had superior overall survival (103.0 vs. 62.9 months; p = .021) despite presenting with larger tumors (9.8 vs. 5.8 cm; p = .041). Concomitant myasthenia gravis was associated with increased recurrence but not worsened mortality.Compared to thymomas, patients with thymic carcinoma presented with higher-stage disease and had poorer 5-year survival (50.0% vs. 93.1%; p < .01). Conclusion:This study affirmed pathologic stage and resectability as prognostic factors for thymic epithelial tumors. New findings include inferior overall survival in female patients and higher recurrence rates in those with thymomas and concomitant myasthenia gravis.

show abstract

Section: Discussionsupporting

confidence: 89%

“…Several investigations have demonstrated a bias for male or female sex as well as no predilection; in this study, no significant difference in incidence was noted between genders. [6][7][8][9][10][11] Relative frequencies of thymoma subtype in this study were A (7.5%), AB (22.5%), B1 (25.0%), B2 (20.0%), and B3 (15.0%), similar to those observed in the literature with subtype A (11%), AB (23%), B1 (17%), and B2 (28%), and B3 (21%). 7 The most significant observed difference between thymoma subtypes on presentation is age at diagnosis.…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Clinical characteristics, prognostic factors, and long‐term outcomes associated with epithelial malignancies of the thymus: A 20‐year single‐institution experience

Altshuler

Mathavan

et al. 2022

Cancer Reports

View full text Add to dashboard Cite

show abstract

“…Briefly, we analyzed data regarding the histologic characteristics of the included studies according to whether they included only patients with thymoma, thymic carcinoma, or mixed type since thymic carcinoma has been considered to be more malignant biologically. 31 It was shown that eight studies included patients with thymoma only, 12 , 14 , 16 , 18 , 21 – 23 , 25 one included patients with thymic carcinoma only, 28 eight with patients of both the histologic types, 13 , 15 , 17 , 19 , 20 , 24 , 26 , 27 while the other two did not provide data regarding thymoma or thymic carcinoma. 10 , 11 …”

Section: Resultsmentioning

confidence: 99%

Postoperative radiotherapy and tumor recurrence after complete resection of stage II/III thymic tumor: a meta-analysis of cohort studies

Ma¹,

Sun²,

Huang³

et al. 2016

OTT

View full text Add to dashboard Cite

BackgroundWhether postoperative radiotherapy (PORT) is effective for reducing the recurrence risk in patients who received complete resection of the stage II or III thymic tumors has not been determined. A meta-analysis was performed by combining the results of all available controlled trials.MethodsPubMed, Cochrane’s Library, and the Embase databases were searched for studies which compared the recurrence data for patients with complete resection of the stage II or III thymic tumors assigned to an observing group, or a PORT group. A random effect model was applied to combine the results.ResultsNineteen studies, all designed as retrospective cohort studies were included. These studies included 663 patients of PORT group and 617 patients of observing group. The recurrence rate for the patients in PORT group and observing group were 12.4% and 11.5%, respectively. Results of our study indicated that PORT has no significant influence on recurrent risk in patients with stage II or III thymic tumor after complete resection (odds ratio 1.02, 95% confidence interval 0.55–1.90, P=0.96). When stratified by stages, our meta-analyses did not indicate any significant effects of PORT on recurrent outcomes in either the stage II or the stage III patients. Moreover, subsequent analysis limited to studies only including patients with thymoma or thymic carcinoma also did not support the benefits of PORT on recurrent outcomes.ConclusionAlthough derived from retrospective cohort studies, current evidence did not support any benefit of PORT on recurrent risk in patients with complete resection of the stage II or III thymic tumors.

show abstract

“…Eighteen studies [14,[17][18][19][20][21][22][23][24]26,[28][29][30][31]33,35,38,39] listed their median follow-up period (40.5-180 mo). www.md-journal.com…”

Section: Study Characteristicsmentioning

confidence: 99%

Prognostic factors for overall survival after surgical resection in patients with thymic epithelial tumors: A systematic review and meta-analysis

Liu

Zhang

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Thymic epithelial tumors (TETs) originate in the thymic epithelial cell, including thymoma and thymic carcinoma. Surgical resection is the first choice for most patients. However, some studies have shown that the factors affecting the prognosis of these patients are not consistent. To evaluate prognostic factors in patients with surgically resected thymic epithelial tumors, we performed a meta-analysis. Methods: We searched the Chinese biomedical literature database, Pubmed, Embase, Cochrane Library and other electronic databases. Studies including postoperative overall survival (OS) and predictors of TETs were included. We made a comprehensive analysis the hazard ratios (HRs) through a single proportional combination. HRs were combined using single proportion combinations. Results: The meta-analysis included 11,695 patients from 26 studies. The pooled OS was 84% at 5 years and 73% at 10 years after TETs operation. The age as continuous-year (HR 1.04, 95% confidence interval (CI) 1.02–1.04), incomplete resection (HR 4.41, 95% CI 3.32–5.85), WHO histologic classification (B2/B3 vs A/AB/B1 HR 2.76, 95% CI 1.25–6.21), Masaoka Stage (stage III/IV vs I/II HR 2.74, 95% CI 2.12–3.55,) were the poor prognostic factors. Conclusions: For patients with TETs after surgical resection, advanced age, incomplete resection, WHO classification B2/B3, and higher Masaoka stage are risk factors for poor prognosis.

show abstract

Thymoma

Cited by 92 publications

References 65 publications

Clinical characteristics, prognostic factors, and long‐term outcomes associated with epithelial malignancies of the thymus: A 20‐year single‐institution experience

Clinical characteristics, prognostic factors, and long‐term outcomes associated with epithelial malignancies of the thymus: A 20‐year single‐institution experience

Postoperative radiotherapy and tumor recurrence after complete resection of stage II/III thymic tumor: a meta-analysis of cohort studies

Prognostic factors for overall survival after surgical resection in patients with thymic epithelial tumors: A systematic review and meta-analysis

Contact Info

Product

Resources

About